29 completed, 4 unknown, 3 terminated, 3 withdrawn. 41 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 41 | Completed 29, Unknown 4, Terminated 3, Withdrawn 3, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow OnabotulinumtoxinA: new trials by email Literature Review of OnabotulinumtoxinA trials Research Report on OnabotulinumtoxinA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis. OnabotulinumtoxinA, Normal saline (placebo) - Base-of-thumb Osteoarthritis, Osteoarthritis | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2025-12-03 | 2026-04-03 |
| A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants OnabotulinumtoxinA, Placebo - Forehead Lines | Phase 3 | Completed | AbbVie | 150 | 2025-01-22 | 2026-05-05 |
| A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants BOTOX, Placebo - Masseter Muscle Prominence | Phase 3 | Completed | AbbVie | 207 | 2024-04-30 | 2026-08-12 |
| A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence BOTOX, Placebo - Masseter Muscle Prominence | Phase 3 | Completed | AbbVie | 202 | 2024-04-22 | 2026-08-25 |
| A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA, Placebo - Moderate to Severe Glabellar Lines | Phase 3 | Completed | Chongqing Claruvis Pharmaceutical Co., Ltd. | 529 | 2023-12-28 | 2024-07-24 |
| A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants BOTOX, Placebo for BOTOX - Masseter Muscle Prominence | Phase 3 | Completed | AbbVie | 259 | 2023-11-22 | 2026-07-06 |
| Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms OnabotulinumtoxinA - Urinary Incontinence, Overactive Bladder Syndrome | Phase 2 / Phase 3 | Active not recruiting | Northwestern University | 66 | 2023-07-13 | 2026-11-06 |
| The Efficacy of Botulinum Toxin vs. Corticosteroid for the Treatment of Refractory Plantar Fasciitis Botulinum Toxin A, Dexamethasone - Plantar Fasciitis | Phase 2 / Phase 3 | Completed | Western Institute for Veterans Research | 62 | 2022-08-23 | 2025-04-02 |
| A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines QM1114-DP, OnabotulinumtoxinA, Placebo - Moderate to Severe Glabellar Lines | Phase 3 | Completed | Galderma R&D | 605 | 2022-07-29 | 2023-10-12 |
| A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence OnabotulinumtoxinA - Platysma Prominence | Phase 3 | Completed | AbbVie | 292 | 2021-11-16 | 2024-12-05 |
| Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines MBA-P01, BOTOX - Glabellar Frown Lines | Phase 3 | Completed | Medytox Korea | 318 | 2021-08-30 | 2022-06-03 |
| A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence OnabotulinumtoxinA, Placebo - Platysma Prominence | Phase 3 | Completed | AbbVie | 426 | 2021-08-10 | 2024-08-20 |
| A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence OnabotulinumtoxinA, Placebo - Platysma Prominence | Phase 3 | Completed | AbbVie | 408 | 2021-07-08 | 2024-11-20 |
| BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence Botulinum Toxin Type A, Placebo - Masseter Muscle Prominence | Phase 3 | Completed | AbbVie | 377 | 2019-08-29 | 2025-05-06 |
| Intracavernous Injection of Botox 100 U for Treatment of PDE5Is Inconvenient Patients With ED OnabotulinumtoxinA, Trimix - Erectile Dysfunction | Phase 2 / Phase 3 | Unknown | Benha University | 124 | 2019-03-10 | 2022-07-19 |
| Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine botulinum toxin Type A - Migraine Disorders | Phase 3 | Withdrawn | Allergan | 2018-01-15 | 2017-07-14 | |
| BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine botulinum toxin Type A, placebo (sodium chloride 0.9 mg) - Migraine Disorders | Phase 3 | Withdrawn | Allergan | 2017-07-03 | 2017-07-14 | |
| Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs) OnabotulinumtoxinA, Topical Aluminium Chloride (cosmetic product) - Hyperhidrosis, Residual Limbs | Phase 3 | Completed | Direction Centrale du Service de Santé des Armées | 54 | 2016-03-01 | 2021-04-28 |
| The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke OnabotulinumtoxinA - Stroke | Phase 3 | Unknown | National Cheng-Kung University Hospital | 150 | 2015-08-01 | 2022-09-30 |
| A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides OnabotulinumtoxinA, Normal Saline - Facial Rhytides, Glabellar Rhytides | Phase 3 | Completed | Allergan | 787 | 2014-10-27 | 2017-07-25 |
Showing 20 of 41. Sign in to see all of them.
Muscle Spasticity (6) · Urinary Bladder, Overactive (6) · Urinary Incontinence (6) · Stroke (5) · Migraine Disorders (3) · Cerebral Palsy (2) · Brain Concussion (1) · Erectile Dysfunction (1) · Fasciitis, Plantar (1) · Fowler Christmas Chapple syndrome (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hyperhidrosis (1) · Multiple Sclerosis (1) · Osteoarthritis (1) · Spinal Cord Injuries (1)
Allergan (19) · AbbVie (8) · National Cheng-Kung University Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Benha University (1) · Chongqing Claruvis Pharmaceutical Co., Ltd. (1) · Christopher Patrick Smith (1) · Direction Centrale du Service de Santé des Armées (1) · Galderma R&D (1) · GlaxoSmithKline (1) · Medytox Korea (1) · Northwestern University (1) · University College, London (1) · University of Washington (1) · Western Institute for Veterans Research (1)
United States (25) · Canada (16) · Belgium (8) · France (7) · Poland (7) · Germany (6) · Czechia (5) · United Kingdom (5) · China (4) · Russia (4) · Turkey (Türkiye) (4) · Italy (3) · South Korea (3) · Taiwan (3) · Hungary (2)
Arlene Lum (2) · Yan Wu (2) · Amy Krambeck, MD (1) · Brenda Jenkins (1) · Christopher P. Smith, MD (1) · Emily McCusker (1) · Margarita Furmanov (1) · Mikol Anderson, DPM (1) · Richard Lin (1)
PMID 24754838, PMID 26231052, PMID 11743295, PMID 15291863, PMID 23608668, PMID 27666156, PMID 29877131, PMID 32665528, PMID 37160401
2014 (3)